Obesity, hypertension and hypercholesterolemia as risk factors for atherosclerosis leading to ischemic events

Current Medicinal Chemistry

Volumn 21, Issue 19, 2014, Pages 2121-2129

  Van Rooy, Mia Jeanne ^a   Pretorius, E ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Atherosclerosis; Hypercholesterolemia; Hypertension; Ischemia; Obesity

Indexed keywords

ADIPONECTIN; ANGIOTENSINOGEN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; CHROMOSOME ABERRATION; ENDOTHELIAL DYSFUNCTION; GENE DISRUPTION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; OBESITY; PHYSIOLOGICAL PROCESS; THROMBOTIC STROKE; TRANSIENT ISCHEMIC ATTACK; BRAIN ISCHEMIA; COMPLICATION; RISK FACTOR;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; OBESITY; RISK FACTORS;

EID: 84899805964     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131227162950     Document Type: Article

References (151)

1. Lusis, A. Atherosclerosis. Nature, 2000, 407(6801), 233-241.
2. Cachofeiro, V.; Miana, M.; de las Heras, N.; Martin-Fernandez, B.; Ballesteros, S.; Balfagon, G.; Lahera, V. Inflammation: A link between hypertension and atherosclerosis. Curr. Hypertens. Rev., 2009, 5(1), 40-48.
3. Herlitz, J.; Wireklint Sundström, B., Bang, A., Berglund, A., Svensson, L., Blomstrand, C. Early identification and delay to treatment in myocardial infarction and stroke: Differences and similarities. Scand. J. Trauma. Resusc. Emerg. Med., 2010, 18, 48-60.
4. Burke, A.; Virmani, R. Pathophysiology of acute myocardial infarction. Med. Clin. North Am., 2007, 91(4), 553-572.
5. Chatterjee, M.; Denney, W.S.; Jing, H.; Diamond, S.L. Systems biology of coagulation initiation: Kinetics of thrombin generation in resting and activated human blood. PLoS Comput. Biol., 2010, 6(9), e1000950.
6. Libby, P.; Ridker, P.M.; Maseri, A. Inflammation and atherosclerosis. Circulation, 2002, 105, 1135-1143.
7. Mallat, Z.; Taleb, S.; Ait-Oufella, H.; Tedgui, A. The role of adaptive T cell immunity in atherosclerosis. J. Lipid. Res., 2009, 50, S364-S369.
8. Formanowicz, D. Do changes in iron metabolism contribute to the accelaration of the atherosclerotic process? . Biotechnologica, 2011, 92(2), 180-192.
9. Hansson G. Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005, 352(16), 1685-1695.
10. Emanuela, F.; Grazia, M.; De Robertis, M.; Luconi, M.P.; Furlani, G.; Boscaro, M. Inflammation a link between obesity and metabolic syndrome. J. Nutr. Metab., 2012, 2012, 476380.
11. Harrison, D. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest., 1997, 100(9), 2153-2157.
12. Ott, I. Soluble tissue factor emerges from inflammation. Circ. Res., 2005, 96(12), 1217-1218.
13. Biswas, S.; Ghoshal, P.K.; Mandal, S.C.; Mandal, N. Relation of anti-to pro-inflammatory cytokine ratios with acute myocardial infarction. Kor. J. Int. Med., 2010, 25(1), 44-50.
14. Demetz, G.; Ott, I. The interface between inflammation and coagulation. Int. J. Inflam., 2012, 2012, 860301.
15. Lipinski, B.; Pretorius, E.; Oberholzer, H.M.; Van der Spuy, W.J. Iron enhances generation of fibrin fibers in human blood: implications for pathogenesis of stroke. Microsc. Res. Tech., 2012, 75(9), 1185-1190.
16. WHO. World Health Report: Reducing risk, promoting healthy life. 2002.
17. Herrera, B.; Lindgren, C.M. The genetics of obesity. Curr. Diab. Rep., 2010, 10(6), 498-505.
18. Orahilly, S. Human genetics illuminates the paths to metabolic disease. Nature, 2009, 462(7271), 307-314.
19. Coll, A.; Farooqi, I.S.; Challis, B.G.; Yeo, G.S.H.; O'Rahilly, S. Proopiomelanocortin and energy balance: insights from human and murine genetics. J. Clin. Endocrinol. Metab., 2004, 89(6), 2557-2562.
20. Hotamisligil, G.; Shargill, N.S.; Spiegelman, B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993, 259(5091), 87-91.
21. Ahima, R.; Flier, J.S. Adipose tissue as an endocrine organ. Trends. Endocrinol. Metab., 2000, 11(8), 327-332.
22. Cinti, S.; Mitchell, G.; Barbatelli, G.; Murano, I.; Ceresi, E.; Faloia, E.; Wang, S.; Fortier, M.; Greenberg, A.S.; Obin, M.S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid. Res., 2005, 46(11), 2347-2355.
23. Trayhurn, P.; Wood, I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr., 2004, 92(3), 347-355.
24. Lyon, C.; Law, R.E.; Hsueh, W.A. Minireview: Adiposity, inflammation and atherogenesis. Endocrinol., 2003, 144(6), 2195-2200.
25. Karastergiou, K.; Mohamed-Ali, V. The autocrine and paracrine roles of adipokines. Mol. Cell. Endocrinol., 2010, 318(1-2), 69-78.
26. Wang, B.; Trayhurn, P. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch., 2006, 452(4), 418-427.
27. Hatziegeorgiou, D.; He, S.; Sobel, J.; Grabstien, K.H.; Hafner, A.; Ho, J.L. IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J. Immunol., 1993, 151(7), 3682-3692.
28. Boos, C.; Lip, G.Y.H. Is hypertension an inflammatory process? Curr. Pharm. Des., 2006, 12(13), 1623-1635.
29. Castell, J.; Gomez-Lechon, M.J.; David, M.; Fabra, R.; Trunllenque, R.; Heinrich, P.C. Acute-phase response of human hepatocytes: regulation of acute phase protein synthesis by interleukin-6. Hepatology, 1990, 12(5), 1179-1186.
30. Ouchi, N.; Kihara, S.; Arita, Y.; Okamoto, Y.; Maeda, K.; Kuriyama, H.; Hotta, K.; Nishida, M.; Takahashi, M.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin, and adipocyte-derived plasma protein, inhibits endothelial NF-β signaling through a cAMP-dependent pathway. Circulation, 2000, 102(11), 1296-1301.
31. Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K.; Mori, Y.; Ide, T.; Murakami, K.; Tsuboyama,-Kasaoka, N.; Ezaki, O.; Akanuma, Y.; Gavrilova, O.; Vinson, C.; Reitman, M.L.; Kagechika, H.; Shudo, K.; Yoda, M.; Nakano, Y.; Tobe, K.; Nagai, R.; Kimura, S.; Tomita, M.; Froguel, P.; Kadowski, T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 2001, 7(8), 941-946.
32. Okamoto, Y.; Kihara, S.; Ouchi, N.; Nishida, M.; Arita, Y.; Kumada, M.; Ohashi, K.; Sakai, N.; Shimimura, I.; Kobayashi, H.; Terasaka, N.; Inaba, T.; Funahashi, T.; Matsuzawa, Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2002, 106(22), 2767-2770.
33. Shek, E.; Brands, MW.; Hall, J.E. Chronic leptin infusion increases arterial pressure. Hypertension,1998, 31(1 pt. 2), 409-414.
34. Buettner, R.; Newgard, C.B.; Rhodes, C.H.; O'Doherty, R.M. Correction of diet-induced hyperglycemia, hyperinsulinemia and skeletal muscle insulin resistance by moderate hyperlipidemia. Am. J. Physiol. Endocrinol. Metab., 2000, 278(3), E563-E569.
35. O'Rourke, L.; Gronning, L.M.; Yeaman, S.J.; Shepherd, P.R. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J. Biol. Chem., 2002, 277(45), 42557-42562.
36. Tham, D.; Martin-McNulty, B.; Wang, Y.X.; Wilson, D.W.; Vergona, R.; Sullivan, M.E.; Dole, W.; Rutledge, J.C. Angiotensin II is associated with activation of NF-KB-mediated genes and downregulation of PPARs. Physiol. Genom., 2002, 11(1), 21-30.
37. Primrose, J.; Davies, J.A.; Prentice, C.R.; Hughes, R.; Johnston, D. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor (PAI-1) activity after surgical treatment of morbid obesity. Thromb. Haemost., 1992, 68(4), 396-399.
38. Folsom, A.; Qamhieh, H.T.; Wing, R.R.; Jefferey, R.W.; Stinson, V.L.; Kuller, L.H.; Wu, K.K. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other haemostatic factors in moderately overweight adults. Arterioscler Thromb., 1993, 13(2), 162-169.
39. Dandona, P.; Weinstock, R.; Thusus, K.; Abdel-Rahman, E.; Aljada, A.; Wadden, T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab., 1998, 83(8), 2907-2910.
40. Itoh, K.; Imai, K.; Masuda, T.; Abe, S.; Tanaka, M.; Koga, R.; Itoh, H.; Matsuyama, T.; Nakamura, M. Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens. Res., 2002, 25(6), 881-886.
41. Ziccardi, P.; Nappo, F.; Giugliano, G.; Esposito, K.; Marfella, R.; Cioffi, M.; D-Andream F.; Molinari, A.M.; Giugliano, D. Reduction of inflammatory cytokine concentrations and improvement if endothelial functions in obese women after weight loss over one year. Circulation, 2002, 105(7), 804-809.
42. Arita, Y.; Kihara, S.; Ouchi, N.; Takahashi, M.; Maeda, K.; Miyagawa, J.; Hotta, K.; Shimomura, I.; Nakamura, T.; Miyaaoka, K.; Kuriyama, H.; Nishida, M.; Yamashita, S.; Okubo, K.; Matsubara, K.; Muraguchii, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun., 1999, 257(1), 79-83.
43. Yang, W.; Lee, W.J.; Funahashi, T.; Tanaka, S.; Matsuzawa, Y.; Chao, C.L.; Chen, C.L.; Tai, T.Y.; Chuang, L.M. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab., 2001, 86(8), 3815-3819.
44. Frostegard, J.; Ulfgren, A.K.; Nyberg, P.; Hedin, U.; Swendenborg, J.; Andersson, U.; Hansson, G.K. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis, 1999, 145(1), 33-43.
45. Han, T.; Sattar, N.; Williams, K.; Gonzalez-Villalpando, C.; Lean, M.E.; Haffner, S.M. Prospective study of C-reactive protein in relation to the development of diabetes and meatbolic syndrome in the Mexico City Diabetes Study. Diabetes Care, 2002, 25(11), 2016-2021.
46. Tsao, P.; McEvoy, L.M.; Drexler, H.; Butcher, E.C.; Cooke, J.P. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation, 1994, 89(5), 2176-2182.
47. Radomski, M.; Palmer, R.M.; Moncada, S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet, 1987, 2(8567), 1075-1058.
48. Villela, N.; Kramer-Aguiar, I.G.; Bottino, D.A.; Wiernsperger, N.; Bouskela, E. Metabolic distrurbances linked to obesity: the role of the impaired tissue perfusion. Arq. Bras. Endocrinol. Metabol., 2009, 53(2), 238-245.
49. Faloia, E.; Giacchetti, G.; Mantero, F. Obesity and hypertension. J. Endocrinol. Invest., 2000, 23(1), 54-62.
50. Kramer-Aguiar, L.; Laflor, C.M.; Bouskela, E. Skin microcirculatory dysfunctions is already present in normoglycemic subjects with metabolic syndrome. Metabolism, 2008, 57(12),1740-1746.
51. He, F.; MacGreggor, G.A. Cost of poor blood pressure control in the UK. J. Hum. Hypertens., 2003, 17(7), 455-457.
52. Hwang, S.; Ballantyne, C.M.; Sharrett, A.R.; Smith, L.C.; Davis, C.E.; Gotto, A.M. Jr.; Boerwinkle, E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation, 1997, 96(12), 4219-4125.
53. Ridker, P.M.; Morrow, D.A. C-reactive protein, inflammation and coronary risk. Cardiol. Clin., 2003, 21(3), 315-325.
54. Geisler, T.; Bhatt, D.L. The role of inflammation in atherothrombosis: current and future strategies of medical treatment. Med. Sci. Monit., 2004, 10(12), RA308-RA316.
55. Schram, M.; Chaturvedi, N.; Schalkwijk, C.G.; Fuller, J.H.; Stehouwer, C.D. EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes. Diabetologia, 2005, 48(2), 370-378.
56. Li, J. Inflammation in hypertension: Primary evidence. Chin. Med. J., 2006, 119(14), 1215-1221.
57. Savoia, C.; Schiffrin, E.L. Inflammation in hypertension. Curr. Opin. Nephrol. Hypertens., 2006, 15(2), 152-158.
58. Bautista, L.E. Inflammation, endothelial dysfunction, and the risk of high blood pressure: Epidemiologic and biological evidence. J. Hum. Hypertens., 2003, 17(4), 223-230.
59. Chrysohoou, C.; Pitsavos, C.; Panangiotakos, D.B.; Skoumas, J.; Stefanadis, C. Association between prehypertension status and the inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am. J. Hypertens., 2004, 17(7), 568-573.
60. King, D.; Egan, B.M.; Mainous, A.G. III.; Geesey, M.E. Elevation of C-reactive protein in people with prehypertension. J. Clin. Hypertens., 2004, 6(10), 562-568.
61. Tilg, H.; Dinarello, C.A.; Mier, J.W. IL-6 and APPs: Antiinflammatory and immunosuppressive mediators. Immunol. Today, 1997, 18(9), 428-432.
62. Rifai, N.; Joubran, R.; Yu, H.; Asmi, M.; Jouma, M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin. Chem., 1999, 45(11), 1967-1973.
63. Brevetti, G.; Silvestro, A.; Di Giacomo, S.; Bucur, R.; Di Donato, A.; Schiano, V.; Scopacasa, F. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J. Vasc. Surg., 2003, 38(2), 374-379.
64. Burnett, J.J. Coronary endothelial dysfunction in the hypertensive patient: From myocardial ischemia to heart failure. J. Hum. Hypertens., 1997, 11(1), 45-49.
65. Lekakis, J.; Papathanassiou, S.; Papaioannou, T.G.; Papamichael, C.M.; Zakopoulos, N.; Kotsis, V.; Dagre, A.G.; Stamatelopoulos, K.; Protogerou, A.; Stamatelopoulos, S.F. Oral L-arginie improves endothelial dysfunction in patients with essential hypertension. Int. J. Cardiol., 2002, 86(2-3), 317-323.
66. Farkas, K.; Kolossvary, E.; Jarai, Z.; Nemcsik, J.; Farsang, C. Noninvasive assessment of microvascular endothelial function by laser Doppler flowmetry in patients with essential hypertension. Atherosclerosis, 2004, 173(1), 97-102.
67. Spieker, L.; Noll, G.; Ruschitzka, F.T.; Maier, W.; Luscher, T.F. Working under pressure: The vascular endothelium in arterial hypertension. J. Hum. Hypertens., 2000, 14(10-11), 617-630.
68. Nadar, S.; Lip, G.Y. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr. Pharm. Des., 2003, 9(21), 1715-1732.
69. Pedrinelli, R. Endothelial dysfunction in hypertension. J. Hum. Hypertens., 2000, 14(8), 481-483.
70. Vanhoutte, P. Endothelial dysfunction in hypertension. J. Hypertens., 1996, 14(5), S83-S93.
71. Klahr, S. The role of nitric oxide in hypertension and renal disease progression. Nephrol. Dial. Transplant., 2001, 16(Suppl. 1), 60-62.
72. Cardaropoli ,S.; Silvagno, F.; Morra, E.; Pescarmona, G.P.; Todros, T. Infectious and inflammatory stimuli decrease endothelial nitric oxide synthase activity in vitro. J. Hypertens., 2003, 21(11), 2103-2110.
73. Taddei, S.; Ghiadoni, L.; Virdis, A.; Versari, D.; Salvetti, A. Mechanisms of endothelial dysfunction: Clinical significance and preventitive non-pharmalogical therapeutic strategies. Curr. Pharm. Des., 2003, 9(29), 2385-2402.
74. Moss, M.; Brunini, T.M.; Soares De Moura, R.; Novaes Malagris, L.E.; Roberts, N.B.; Ellroy, J.C.; Mann, G.E.; Mendes Ribeiro, A.C. Diminshed L-arginine bioavailability in hypertension. Clin. Sci. (Lond)., 2004, 107(4), 391-397.
75. Pieczenik, S.; Neustadt, J. Mitochondrial dysfunction and molecular pathways of disease. Exp. Mol. Pathol., 2007, 83(1), 84-92.
76. Touyz, R. Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev. Cardiovasc. Ther., 2003, 1(1), 91-106.
77. Touyz, R.; Schiffrin, E.L. Reactive oxygen species in vascular biology: Implications in hypertension. Histochem. Cell. Biol., 2004, 122(4), 339-352.
78. Portaluppi, F.; Boari, B.; Manfredini, R. Oxidative stress in essential hypertension. Curr. Pharm. Des., 2004, 10(14), 1695-1698.
79. Touyz, R.; Tabet, F.; Schiffrin, E.L. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin. Exp. Pharmacol. Physiol., 2003, 30(11), 860-866.
80. Cai, H.; Harrison, D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res., 2000, 87, 840-844.
81. Taniyama, Y.; Griendling, K.K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension, 2003, 42(6), 1075-1081.
82. Tanito, M.; Nakamura, H.; Kwon, Y.W.; Teratani, A.; Masutani, H.; Shioji, K.; Kishimoto, C.; Ohira, A.; Horie, R.; Yodoi, J. Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxid. Redox. Signal., 2002, 6(1), 89-97.
83. Chabrashvili, T.; Tojo, A.; Onozato, M.L.; Kitiyakara, C, Quinn, M.T., Fujita, T., Welch, W.J., Wilcox, C.S. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension, 2002, 39(2), 269-274.
84. Higashi, Y.; Sasaki, S.; Nakagawa, K.; Matsuura, H.; Oshima, T.; Chayama, K. Endothelial function and oxidative stress in renovascular hypertension. N. Engl. J. Med., 2002, 346(25), 1954-1962.
85. Lip, G.; Edmunds, E.; Nuttall, S.L.; Landray, M.J.; Blann, A.D.; Beevers, D.G. Oxidative stress in malignant and non-malignant phase hypertension. J. Hum. Hypertens., 2002, 16(5), 333-336.
86. Kishi, T.; Hirooka, Y.; Kimura, Y.; Ito, K.; Shimokawa, H.; Takeshita, A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in strokeprone spontaneously hypertensive rats. Circulation, 2004, 109(19), 2357-2362.
87. Kannel, W. Risk stratification in hypertension: new insights from the Framingham study. Am. J. Hypertens., 2000, 13(1 pt. 2), 3S-10S.
88. Mancia, G.; Parati, G.; Borhi, C.; Ghronzi, G.; Andriani, E.; Marinelli, L.; Valentini, M.; Tessari, F.; Ambrosioni, E.; SMOOTH investigators. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J. Hypertens., 2006, 24(5), 837-843.
89. Borghi, C.; Grassi, G.; Taddei,S. Interactions between hypertension and hypercholesterolemia: From epidemiology to therapeutic implications. Curr. Hypertens. Rev., 2008, 4(1), 1-7.
90. Sander, G.; Giles, T.D. Hypertension and lipids: lipid factors in the hypertension syndrome. Curr. Hypertens. Rep., 2002, 4(6), 458-463.
91. Stokes, K.; Cooper, D.; Tailor, A.; Granger, D.N. Hypercholesterolemia promotes inflammation and microvscualr dysfunction: A role of nitric oxide and superoxide. Free Radic. Biol. Med., 2002, 33(8), 1026-1036.
92. Ross, R. Atherosclerosis an inflammatory disease. N. Engl. J. Med., 1999, 340(2), 115-126.
93. Scheidigger, K.; Butler, S.; Witztum, J.L. Angiotenin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J. Biol. Chem., 1997, 272(34), 21609-21615.
94. Grote, K.; Drexler, H.; Schieffer, B. Renin-angiotensin system and atherosclerosis. Nephrol. Dial. Transplant., 2004, 19(4), 770-773.
95. Cheng, Z.; Vapaatalo, H.; Mervaala, E. Angiotensin II and vascular inflammation. Med. Sci. Monit., 2005, 11(6), RA194-RA205.
96. Wassman, S.;Nickenig, G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J. Hypertens. Suppl., 2006, 24(1), S15-S21.
97. Nickenig, G.; Harrison, D.G. The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part I: Oxidative stress and atherogenesis. Circulation, 2002, 105(3), 393-396.
98. Nickenig, G.; Harrison, D.G. The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part II: AT1-type receptor upregulation. Circulation, 2002, 105(4), 530-536.
99. Laursen, J.; Rajagolapan, S.; Galis, Z.; Tarpey, M.; Freeman, B.A.; Harrison, D.G. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation, 1997, 95(3), 588-593.
100. Steinberg, D. Hypercholesterolemia and inflammation in atherogenesis: two sides to the same coin. Mol. Nutr. Food. Res., 2005, 49(11), 995-998.
101. Glagov, S.; Zarins, C.; Giddens, D.P.; Ku, D.N. Haemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries. Arch. Pathol. Lab. Med., 1988, 112(10), 1018-1031.
102. Steinberg, D. Antioxidants and atherosclerosis. A current assessment. Circulation, 1991, 84(3), 1420-1425.
103. Liao, F.; Andalibi, A.; Qiao, J.H.; Allayee, H.; Fogelman, A.M.; Lusis, A.J. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction and aortic fatty streak formation in mice. J. Clin. Invest., 1994, 94(2), 877-884.
104. Gong, K.; Zhu, GY.; Wang, L.H.; Tang, C.S. Effect of active oxygen species on intimal proliferation in rat aorta after arterial injury. J. Vasc. Res., 1996, 33(1), 42-46.
105. Scalia, R.; Appel, J.Z. III.; Lefer, A.M. Leukocyte-endothelium interaction during the early stages of hypercholesterolaemia in the rabbit tole of P-selectin, ICAM-1 and VCAM-1. Arterioscler. Thromb. Vasc. Biol., 1998, 18(7), 1093-1100.
106. Napoli, C.; Lerman, L.O. Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolaemia. Mayo Clin. Proc., 2001, 76(6), 619-631.
107. Haak, E.; Abletshauser, C.; Weber, S.; Goedicke, C.; Martin, N.; Hermanns, N.; Lackner, K.; Kusterer, K.; Usadel, K.H.; Haak, T. Fluvastatin therapy improves microcirculation in patients with hyperlipidemia. Atherosclerosis, 2001, 155(2), 395-401.
108. Vink, A.; Constantinescu, A.A.; Spaan, J.A. Oxidized lipoproteins degrade the endothelial surface layer: Implications for plateletendothelial cell adhesion. Circulation, 2000, 101(13), 1500-1502.
109. Tailor, A.; Granger, D.N. Acute hypercholesterolemia and ischaemia/ reperfusion-induced blood cell-endothelial cell adhesion in the murine mesenteric vascular bed. FASEB J., 2001, 15, A35.
110. Lehr, H.; Olofsson, A.M.; Carew, T.E.; Vajkoczy, P.; von Adrian, U.H.; Hubner, C.; Berndt, M.C.; Steinberg, D.; Messmer, K.; Arfors, K.E. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab. Invest., 1994, 71(3), 380-386.
111. Granger, D. Ischemia/reperfusion mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation, 1999, 6(3), 167-178.
112. Fuster, V.; Badimon, L.; Badimon, J.; Chesebro, J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med., 1992, 326(4), 242-250.
113. Osborn, L.; Hession, C.; Tizard, R.; Vassallo, C.; Luhowskyj, S.; Chi-Rosso, G.; Lobb, R. Direct expression cloning of vascular cell adhesion molecule I, a cytokine-induced endothelial protein that binds to lymphocytes. Cell, 1989, 59(6), 1203-1211.
114. Osborn, L. Leukocyte ashesion to endothelium in inflammation. Cell, 1990, 62(1), 3-6.
115. Cybulsky, M.; Gimbrone, M.A. Jr.; Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science, 1991, 251(4995), 788-791.
116. Poston, R.; Haskard, D.O.; Coucher, J.R.; Gall, N.P.; Johnsin-Tidey, R.R. Expression of intercellular adhesion molecule-I In atherosclerotic plaques. Am. J. Pathol., 1992, 140(3), 665-673.
117. Nagel, T.; Resnick, N.; Atkinson, W.J.; Dewey, C.F. Jr.; Gimbrone, M.A. Jr. Shear stress selectively upregulates intercellular adhesion molecule-I expression in cultured human vascular endothelial cells. J. Clin. Invest., 1994, 94(2), 198-204.
118. Navab, M.; Jama, S.Y.; Nguyen, T.B.; Fogelman, A.M. Monocyte adhesion and transmigration in atherosclerosis. Coron. Artery Dis., 1994, 5(3), 198-204.
119. Nakashima, Y.; Raines, E.W.; Plump, A.S.; Breslow, J.L.; Ross, R. Upregulation of VCAM-I and ICAM-I at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Atheroscler. Thromb. Vasc. Biol., 1998, 18(5), 842-851.
120. Libby, P. Changing concepts of atherogenesis. J. Intern. Med., 2000, 247(3), 349-358.
121. Aqel, N.; Ball, R.Y.; Waldmann, H.; Mitchinson, M.J. Monocytic origin of foam cells in human atherosclerotic plaques. Am. J. Pathol., 1984, 140(3), 265-271.
122. Stary, H. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis, 1989, 9(1 Suppl), I19-I32.
123. Steinberg, D.; Parthasarathy, S.; Carew, T.E.; Khoo, J.C.; Witztum, J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med., 1989, 320(14), 915-924.
124. Ylä-Herttuala, S.; Palinski, W.; Rosenfeld, M.E.; Parthasarthy, S.; Carew, T.E.; Butler, S.; Witztum, J.L.; Steinberg, D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest., 1989, 84(4), 1086-1095.
125. Libby, P.; Warner, S.J.; Salomon, R.N.; Birinyi, L.K. Production of platelet-derived growth factor-like mitogen by smooth muscle cells from human atheroma. N. Engl. J. Med., 1988, 318(23), 1493-1498.
126. Raines, E.; Dower, S.K.; Ross, R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science, 1989, 243(4889), 393-396.
127. Mantovoni, A.; Bussolino, F.; Dejana, E. Cytokine regulation of endothelial cell function. FASEB J., 1992, 6(8), 2591-2599.
128. Rus, H.; Vlaicu, R.; Niculescu, F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis, 1996, 127(2), 263-271.
129. Sukovich, D.; Kauser, K.; Shirley, F.D.; Del Vecchia, V.; Halks-Miller, M.; Rubsnyl, G.M. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: Inhinbition by 17beta-estradiol. Arterioscler. Thromb. Vasc. Biol., 1998, 18(9), 1498-1505.
130. Mitchinson, M.B.;Ball, R.Y. Macrophages and atherogenesis. Lancet, 1987, 330(8551), 146-149.
131. Schwartz, S.; Reidy, M.A. Common mechanism of proliferation of smooth muscle in atherosclerosis and hypertension. Hum. Pathol., 1987, 18(3), 240-247.
132. Winkels, J.; Friesel, R.; Burgess, W.H.; Howk, R.; Mehlman, T.; Weinstein, R.; Maciaq, T. Human vacular smooth muscle cells both express and respond to heparin-binding growth factor I (endothelial growth factor). Proc. Natl. Acad. Sci. USA., 1987, 84(20), 7124-7128.
133. Ikeda, U.; Ikeda, M.; Oohara, T.; Oquchi, A.; Kamitani, T.; Tsuruyo, Y.; Kano, S. Interleukin-6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am. J. Physiol., 1991, 260(5 pt. 2), H1713-H1717.
134. Davies, M. A macro and micro view of coronoary vascular insult in ischemic heart disease. Circulation, 1990, 82(3 Suppl), II38-II46.
135. Ip, J.; Fusterm, V.; Badimon, J.; Taubman, M.B.; Chesebro, J.H. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J. Am. Coll. Cardiol., 1990, 15(7), 1667-1687.
136. Libby, P. Molecular bases of the acute coronary syndromes. Circulation, 1995, 91, 2844-2850.
137. Bethesda, M.I. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults Adult Treatment Panel. NIH: National Heart, Lung and Blood Institute, 1993.
138. Ross, R.; Glomset, J.A. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science, 1973, 180(4093), 1332-1339.
139. Ross, R.; Glomset, J.A. The pathogenesis of atherosclerosis. N. Engl. J. Med., 1976, 295, 420-425.
140. Ross, R. The pathogenesis of atherosclerosis - an update. N. Engl. J. Med., 1986, 314(8), 488-500.
141. Ross, R. The pathogenesis of atherosclerosis: A perspective for the 1990's. Nature, 1993, 362(6423), 801-809.
142. Glagov, S.; Weisenberg, E.; Zarins, C.K.; Stankunavicius, R.; Kolettis, GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med., 1987, 316(22), 1371-1375.
143. Fuster, V. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation, 1994, 90(4), 2126-2146.
144. Lee, R.; Libby, P. The unstable atheroma. Arterioscler.Thromb. Vasc. Biol., 1997, 17, 1859-67.
145. Falk, E.; Shah, PK.; Fuster, V. Pathogenesis of plaque disruption. Philadelphia, USA: Lippincott-Raven; 1996.
146. Babior, B. NADPH oxidase: An update. Blood, 1999, 93(5), 1464-1476.
147. Lipinski, S.; Bremer, L.; Lammers, T.; Thieme, F.; Schreiber, S.; Reosenstiel, P. Coagulation and inflammation. Molecular insights and diagnsotic implications. Hamostaseologie, 2011, 31(2), 94-104.
148. Albers, G.; Caplan, L.R.; Coull, B.M. Transient ischaemic attack: proposal for a new definition. N. Engl. J. Med., 2002, 347(21), 1713-1716.
149. Shah, K. Edlow, J.A. Transient ischaemic attack: Review for the emergency physician. Ann. Emerg. Med., 2004, 43(5), 592-604.
150. Rost, N.; Wolf, P.A.; Kase, C.S.; Kelly-Hayes, M.; Silbershatz, H.; Massaro, J.M.; D'Agostino, R.B.; Franzblau, C.; Wilson, P.W.F. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemica attack - The Farmingham Study. Stroke, 2001, 32(11), 2575-2579.
151. Burns, J.; Rabinstein, A.A.; Roger, V.L.; Stead, L.G.; Christianson, T.J.; Killian, J.M.; Brown, R.D. Jr. Incidence and predictors of myocardial infarction after transient ischameic attack: a populationbased study. Stroke, 2011, 42(4), 935-940.